Citations 1
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a
Chanan‐Khan, Asher , Mudenda, Boyd, Nogaieva, Larysa, Usenko, Hanna, Perekhrestenko, Tetiana , Muzhychuk, Ivan, Myasnikov, Alexander G., Maslyak, Zvenyslava, Proidakov, Andrew, Uspenskaya, Olga, Borisenkova, Elena , Marlton, Paula , Winter, Allison , Lysa, Tamila, Fu, Lei, Glass, Laura A., Ahmad, Mohammad, Карпенко, Олена, Osipov, Iurii , De, Asit K. , Paudyal, Ben, Wang, Hengbang , Winkler, Robert L. , Gabrail, Nashat , Ganju, Vinod , Константинова, Т. С. , Samoylova, Olga, Yang, Dajun , Davids, Matthew S. , Kriachok, Iryna , Ivanov, Vladimir, Kyselova, Olena , Myasnikov, Alexander, Uspenskaya, Olga, Siddiqi, Tanya , Бакиров, Б. А. , Chen, Zi , Yu, Min , Li, Mingyu , Glass, Laura, Karpenko, Olena, De, Asit, Winkler, Robert, Zhai, Yifan
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2326-2328
